Breaking News from the Early/Expanded Access Committee - Now available in New Orleans, LA
(future potential sites include AZ, CA, FL, MA, MO, NV, PA, SC, TX, WV - check link below):
Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
No placebo - No cost for Alpharadin (check with trial site for any other costs)
Basic Eligibility Criteria:
- CRPC/HRPC - on hormone therapy with progressive disease
- At least 2 bone metastases - blastic (sclerotic), not lytic
- Some amount of pain/bone pain (must be taking daily meds – even if it’s Tylenol)
- No mets to lung, liver, or brain
- HGB 10.0 or higher
- Previously treated with Taxotere (or have refused Taxotere – patient’s choice)
- 4 weeks since chemo, and No chemo currently planned
- No abiraterone (Zytiga) while on Alpharadin - previous OK
- No previous extensive radiation to bone (> 25% of bone marrow), and no previous Quadramet or Strontium 89
If you think you fit the above criteria, contact Patrick Cotogno, or Oliver Sartor MD for further screening at:
Tulane University
1415 Tulane Ave. HC-62
New Orleans, LA 70112
Phone: (504) 988-2735
Principle Investigator: [email protected]
Study Coordinator: [email protected]
* For more on Alpharadin (Radium 223), read Dr Sartor's article on PAGE 9 of PAACT's March 2012 newsletter